Celularity (CELU) Cash & Equivalents (2018 - 2025)

Celularity (CELU) has reported Cash & Equivalents for 8 consecutive years, with $6.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 736.72% year-over-year to $6.2 million; the TTM figure through Dec 2025 stood at $6.2 million (up 736.72% YoY), while the FY2025 annual figure was $6.2 million, up 736.72% from the prior year.
• Cash & Equivalents rose to $6.2 million in Q4 2025 per CELU's latest filing, from $120000.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $73.3 million in Q3 2021 and bottomed at $211.0 in Q2 2021.
• Historically, Cash & Equivalents has averaged $13.8 million across 5 years, with a median of $1.4 million in 2024.
• Annual changes were most pronounced in 2021 — Cash & Equivalents tumbled 99.97% — and 2022, when it soared 18007482.94%.
• Celularity's Cash & Equivalents stood at $37.2 million in 2021, then sank by 62.5% to $14.0 million in 2022, then tumbled by 98.37% to $227000.0 in 2023, then jumped by 225.11% to $738000.0 in 2024, then soared by 736.72% to $6.2 million in 2025.
• Business Quant data shows CELU's Cash & Equivalents at $6.2 million in Q4 2025, $120000.0 in Q3 2025, and $863000.0 in Q2 2025.